Ligand Pharmaceuticals News

Ligand Pharmaceuticals Inc. said Friday a European advisory committee recommended approval of the blood disorder treatment Revolade.

BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors has Healthcare stock news and updates to its calendar database of Clinical Trials and upcoming FDA approvals & decisions.

Nov 20, 2009 - Ligand Pharmaceuticals Incorporated today announced that data from a preclinical study on its selective androgen receptor modulator LGD-4033 was featured in a poster presentation at the 62nd Annual Meeting of the Gerontology Society of America in Atlanta.

Ligand Pharmaceuticals Inc. said Thursday it received a $2 million milestone payment from Merck & Co.

San Diego-based biopharmaceuticals firms Ligand Pharmaceuticals and Metabasis Therapeutics announced this morning that Ligand is acquiring Metabasis, in a deal worth $3.2M in cash plus rights to receive payments from any royalties or licensing of programs in the future.

Ligand Pharmaceuticals Inc. will buy Metabasis Therapeutics Inc. for about $3.2 million and contingent future payments, the companies said Tuesday.

Both Metabasis Therapeutics and Ligand Pharmaceuticals have long histories in San Diego.

Paul Maier will be reporting directly to the company's interim chief executive officer and board chairman, Harry Hixson.

SmarTrend, our proprietary pattern recognition system, called a Downtrend for Ligand Pharmaceuticals on August 31, 2009 at $2.40. Since then, Ligand Pharmaceuticals has returned 9.2% as of today's recent price of $2.18. Want to profit from these alerts? Go to www.mysmartrend.com now for a FREE two-week trial.

The program is designed to expand customer awareness of third-par... PARIS-- --Regulatory News: The Warsaw Court of Appeals denied the request of Deutsche Telekom and Elektrim for the recognition in the Republic of Poland of the arbitral award render... SAN DIEGO-- --Ligand Pharmaceuticals Incorporated today announced that pursuant to an amendment ...

Sep 9, 2009 - Ligand Pharmaceuticals Incorporated announced that President and Chief Executive Officer John L. Higgins and Vice President, Business Development and Strategic Planning Syed Kazmi made a presentation today at the Thomas Weisel Partners Healthcare Conference in Boston.

With raw data rapidly approaching 2 TB,... NEW YORK-- --Bruce Berger and Nat Wasserstein, longtime partners in the distressed asset and turnaround space are launching a new private investment firm.

News and FDA Updates for Walgreens , Caterpillar , Ligand , IMS Health Headlines and biomedical stock developments from BioMedReports.Com Pasadena, CA - 08/27/09 - BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors has ...

Ligand Pharmaceuticals Incorporated announced today that John L. Higgins, President and Chief Executive Officer, will be presenting at the Thomas Weisel Partners Healthcare Conference 2009 on Wednesday, September 9, at 9:10 a.m. Eastern time.

SAN DIEGO & BRANFORD, Conn.-- --Aug 24, 2009 - Ligand Pharmaceuticals Incorporated and Neurogen Corporation announced today they have entered into a definitive merger agreement under which Ligand will acquire Neurogen.

BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors has Healthcare stock news and updates to its calendar database of Clinical Trials and upcoming FDA approvals & decisions.

Neurogen Corp. , the embattled drug developer in Branford, Conn., has entered a merger agreement in which the company will be sold to Ligand Pharmaceuticals Inc., a San Diego biotechnology firm, for an estimated $11 million in an upfront Ligand common stock offering to Neurogen shareholders.

Drug developers Neurogen Corp . in Branford and Ligand Pharmaceuticals Inc . in San Diego are merging, with Ligand to emerge as the surviving entity, the companies said today.

Ligand Pharmaceuticals Incorporated announced today the mutual termination of its collaboration and license agreement with N.V. Organon, which Ligand assumed in connection with its acquisition of Pharmacopeia in December 2008.

San Diego-based Ligand Pharmaceuticals Inc. and N.V. Organon have mutually terminated their collaboration and license agreement, which Ligand inherited after its acquisition of Pharmacopeia in December.